Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Lycia Therapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
Lycia Therapeutics

Lycia Therapeutics

Series B

Leading in extracellular protein degradation with our innovative LYTAC platform.

HQ
South San Francisco, CA, US
Founded
2019
Overview
Compare
Fundraising
Employees
Website

Lycia Therapeutics was founded with the mission to revolutionize the treatment of diseases by targeting and degrading extracellular proteins. The company leverages its proprietary LYTAC (Lysosomal Targeting Chimera) platform to develop innovative therapies aimed at depleting difficult-to-drug targets. Lycia's core focus is on creating first-in-class extracellular protein degraders, addressing unmet medical needs across various therapeutic areas.

Notable affiliates include leading scientists and industry experts who contribute to the company's strategic direction and innovation. Lycia has garnered significant interest from top-tier investors, aiding in its rapid development and growth. The company's groundbreaking work with the LYTAC platform has positioned it as a leader in the field of extracellular protein degradation, promising substantial impact on future therapeutic approaches and patient outcomes.

Lycia Therapeutics - Similar Companies

Avilar Therapeutics logo

Avilar Therapeutics

avilar-tx.com

Lytica Therapeutics logo

Lytica Therapeutics

Biotheryx logo

Biotheryx

biotheryx.com

EpiBiologics logo

EpiBiologics

epibiologics.com

Plexium logo

Plexium

plexium.com

76Bio logo

76Bio

76bio.com

LyGenesis logo

LyGenesis

lygenesis.com

Lysosomal Therapeutics logo

Lysosomal Therapeutics

lysosomaltx.com

Kymera Therapeutics logo

Kymera Therapeutics

kymeratx.com

Libra Therapeutics logo

Libra Therapeutics

Vicinitas Therapeutics logo

Vicinitas Therapeutics

vicinitastx.com

Lyra Therapeutics logo

Lyra Therapeutics

Lykos Therapeutics logo

Lykos Therapeutics

lykospbc.com

ExoLytics logo

ExoLytics

exolytics.com

Juvena Therapeutics logo

Juvena Therapeutics

Lycia Therapeutics - Quick Facts

Who are Lycia Therapeutics' competitors?

Companies similar to Lycia Therapeutics include Avilar Therapeutics, Lytica Therapeutics, Biotheryx and EpiBiologics.

When was Lycia Therapeutics founded?

Lycia Therapeutics was founded in 2019.

Where is Lycia Therapeutics' headquarters located?

Lycia Therapeutics' headquarters is located in South San Francisco, CA, US.

When was Lycia Therapeutics' last funding round?

Lycia Therapeutics' most recent funding round was for $70M (USD) in September 2021.

How much has Lycia Therapeutics raised to-date?

As of Sep 9, 2021, Lycia Therapeutics has raised a total of $120M (USD).

How many employees does Lycia Therapeutics have?

Lycia Therapeutics has 42 employees as of Feb 5, 2024.

Lycia Therapeutics - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Protein Degradation
Tags
  • Platform
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified